Compare Nuvalent Inc (NUVL) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Banco Santander SA — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Banco Santander SA trades at $13.7 (market cap $191.46B). The key difference: Banco Santander SA is far larger — about 19.5× Nuvalent Inc's market cap, and Banco Santander SA pays a 2.09% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| NUVL | SAN | |
|---|---|---|
Market Cap | $9.81B | $191.46B |
Sector | Technology | Financials |
52-Week High | $123.96 | $14.37 |
52-Week Low | $72.16 | $8.40 |
Enterprise Value | $8.52B | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
Santander (SAN) trades at $13.65, up 0.74% with mixed technical signals showing bearish moving averages but oversold RSI. The company reported Q1 2026 EPS beat ($0.41 vs $0.29 expected) and maintains strong profitability with 26.72% net margin and 16.18% ROE. Recent developments include the $12.2 billion Webster Bank acquisition and AI-driven cost initiatives targeting $1.15 billion in business value.
SAN offers value with a 13.23 P/E and dividend yield near 4.4%, supported by 64% analyst buy ratings. Key risks include declining cash flows (-$28.13B in 2024) and Spanish antitrust probes. The stock's upside depends on successful integration of acquisitions and AI efficiency gains offsetting macroeconomic pressures on European banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
